Paper12374981
The polycomb group protein EZH2 is involved in progression of prostate cancer.
Varambally S and 11 others. Nature, 2002. Cited by 2,226 papers, by iCite.
Cite this record
ConductScience Library. The polycomb group protein EZH2 is involved in progression of prostate cancer. Papers, record 12374981. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/12374981
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drosophila Proteins | Major topic |
| Gene Expression Regulation, Neoplastic | Major topic |
| Nuclear Proteins | Major topic |
| Prostatic Neoplasms | Major topic |
| Repressor Proteins | Major topic |
| Biomarkers, Tumor | |
| Disease Progression | |
| Gene Expression Profiling | |
| Gene Silencing | |
| Genes, Tumor Suppressor | |
| Humans | |
| Male | |
| Molecular Sequence Data | |
| Oligonucleotide Array Sequence Analysis | |
| Phenotype | |
| Polycomb Repressive Complex 2 | |
| Predictive Value of Tests | |
| RNA, Messenger | |
| RNA, Small Interfering | |
| Transfection | |
| Treatment Outcome | |
| Tumor Cells, Cultured |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 12374961 | Cancer. The silence of the genes. | https://conductscience.org/library/papers/12374961 |
Source PubMed
Cited by1,351
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2,226 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42950024 | A systematic pan-cancer analysis of intratumoral microbiota-derived epitopes to inform cancer immunotherapy and prevention. | Sci Adv | 2026 | https://conductscience.org/library/papers/42950024 | PubMed |
| 42877356 | DNA Methylation and TMPRSS2-ERG Fusion Status in Patients with Prostate Cancer from The Republic of North Macedonia. | Balkan J Med Genet | 2026 | https://conductscience.org/library/papers/42877356 | PubMed |
| 42794930 | A Multiplex RT-QPCR Assay of ONECUT2, EZH2, and BRCA2 for the Detection of Clinically Significant Prostate Cancer in Needle Biopsies. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42794930 | PubMed |
| 42761779 | Histone modifications: mechanisms, metabolic regulation, and therapeutic targeting in cancer. | Precis Clin Med | 2026 | https://conductscience.org/library/papers/42761779 | PubMed |
| 42754954 | Advancements and future directions in transforming therapies of prostate cancer. | Chin Med J (Engl) | 2026 | https://conductscience.org/library/papers/42754954 | PubMed |
| 42601451 | An EZH2-SREBP2 axis promotes cholesterol biosynthesis and represents a noncanonical vulnerability in tumorigenesis. | Nat Cell Biol | 2026 | https://conductscience.org/library/papers/42601451 | PubMed |
| 42599162 | EZH2 Inhibition and Myeloid Risk: A Feature of On-Target Biology. | Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42599162 | PubMed |
| 42591989 | The molecular underpinnings of the immune landscape in prostate cancer: decoding a "cold" tumor. | Front Oncol | 2026 | https://conductscience.org/library/papers/42591989 | PubMed |
| 42589556 | WSB1-Mediated PSMA Ubiquitination Promotes Enzalutamide-Induced Neuroendocrine-like Transition in Patient-Derived Prostate Cancer Spheroids. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42589556 | PubMed |
| 42589296 | Integrated miRNA Sequencing and Network Analysis Reveal a Molecular Continuum Between Peritumoral and Tumor Tissue in Prostate Cancer. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42589296 | PubMed |
| 42553046 | NNMT Loss Drives Cancer Progression by enhancing SAM availability for mTORC1 Signaling and Chromatin Methylation. | bioRxiv | 2026 | https://conductscience.org/library/papers/42553046 | PubMed |
| 42443217 | Oncogenic Ras drives EED degradation and PRC2 dysfunction to promote aggressive squamous cell carcinoma. | Nat Commun | 2026 | https://conductscience.org/library/papers/42443217 | PubMed |
| 42260416 | Integrated multi-omics profiling uncovers the epigenetic, transcriptional, and metabolic landscape of prostate cancer progression. | BMC Cancer | 2026 | https://conductscience.org/library/papers/42260416 | PubMed |
| 42252277 | Neuroendocrine tumours through an epigenetic lens: Emerging insights for diagnosis and treatment. | J Neuroendocrinol | 2026 | https://conductscience.org/library/papers/42252277 | PubMed |
| 42225614 | Multi-omics analyses identify EZH2 as a central driver in rhabdomyosarcoma radioresistance and highlight Tazemetostat as an effective radiosensitizer in vitro and in vivo. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42225614 | PubMed |
| 42219643 | Ion chromatography-ultra-high-resolution mass spectrometry reveals EZH2-driven reprogramming of nucleic acid and protein methylation. | Anal Chim Acta | 2026 | https://conductscience.org/library/papers/42219643 | PubMed |
| 42213546 | Molecular determinants of AR-enhancer interaction and cistrome reprogramming in prostate cancer progression. | Endocr Relat Cancer | 2026 | https://conductscience.org/library/papers/42213546 | PubMed |
| 42211521 | The role of EZH2 dysregulation in the pathogenesis of B-cell lymphomas and its implications as a target therapy. | Front Oncol | 2026 | https://conductscience.org/library/papers/42211521 | PubMed |
| 42170760 | Interplay of the 3D genome and epigenome in androgen-driven prostate cancer. | Epigenomics | 2026 | https://conductscience.org/library/papers/42170760 | PubMed |
| 42140904 | NRF1 predominantly causes EZH2 overexpression in cancer cells. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42140904 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AMACR | 23600 | PubTator's text mining | https://conductscience.org/library/genes/23600 | NCBI Gene |
| EZH2 | 2146 | PubTator's text mining | https://conductscience.org/library/genes/2146 | NCBI Gene |
Data2
The data bank entries PubMed's record names. Trial numbers are under Trials.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Drugs
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/12374981
GET https://conductscience.org/api/papers/v1/12374981/cited_by?page=2